Log in

Relevant bibliographies by topics / Daunorubicin

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Daunorubicin'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Daunorubicin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Daunorubicin"

1

Drevin, Guillaume, Marie Briet, Caroline Bazzoli, et al. "Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial." Pharmaceutics 14, no. 4 (2022): 792. http://dx.doi.org/10.3390/pharmaceutics14040792.

Full text

Abstract:

Daunorubicin pharmacokinetics (PK) are characterised by an important inter-individual variability, which raises questions about the optimal dose regimen in patients with acute myeloid leukaemia. The aim of the study is to assess the joint daunorubicin/daunorubicinol PK profile and to define an optimal population PK study design. Fourteen patients were enrolled in the PK ancillary study of the BIG-1 trial and 6–8 samples were taken up to 24 h after administration of the first dose of daunorubicin (90 mg/m2/day). Daunorubicin and daunorubicinol quantifications were assessed using a validated liq

APA, Harvard, Vancouver, ISO, and other styles

2

Zucchetti, Massimo, Amerigo Boiardi, Antonio Silvani, Idria Parisi, Stefano Piccolrovazzi, and Maurizio D'Incalci. "Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin." Cancer Chemotherapy and Pharmacology 44, no. 2 (1999): 173–76. http://dx.doi.org/10.1007/s002800050964.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Daunorubicin see Cytarabine/daunorubicin." Reactions Weekly &NA;, no. 354 (1991): 8. http://dx.doi.org/10.2165/00128415-199103540-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Choi, Min-Koo, Im-Sook Song, Dae-Duk Kim, Suk-Jae Chung, and Chang-Koo Shim. "Altered Pharmacokinetics of Daunorubicin in Rats with CCl4-Induced Hepatic Injury." Journal of Pharmacy & Pharmaceutical Sciences 10, no. 4 (2007): 443. http://dx.doi.org/10.18433/j3mw28.

Full text

Abstract:

PURPOSE. The effect of CCl4-induced experimental hepatic injury (CCl4-EHI) on the pharmacokinetics of daunorubicin was investigated systemically in rats, in an attempt to elucidate the major determinants of the effect of CCl4-EHI on the pharmacokinetics of the drug. METHODS. CCl4-EHI was induced in rats by a single intraperitoneal injection of CCl4 (1mL/kg rat), and a 24 h fasting period. Daunorubicin was administered intravenously to control and EHI rats at a dose of 11.3 mg/mL/kg and the in vivo pharmacokinetics was studied. The in vitro uptake of the drug into isolated hepatocytes and canal

APA, Harvard, Vancouver, ISO, and other styles

5

Cusack, B. J., Stephan P. Young, Robert E. Vestal, and Richard D. Olson. "Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat." Cancer Chemotherapy and Pharmacology 39, no. 6 (1997): 505–12. http://dx.doi.org/10.1007/s002800050606.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Nikanjam, Mina, Edmund Capparelli, Jeffrey E. Lancet, Jonathan E. Kolitz, Arthur C. Louie, and Gary J. Schiller. "Enhanced Cytarabine and Daunorubicin Population Pharmacokinetics When Administered As CPX-351: A Novel Liposomal Formulation Not Requiring Dose Reduction for Mild Renal or Hepatic Dysfunction." Blood 128, no. 22 (2016): 3955. http://dx.doi.org/10.1182/blood.v128.22.3955.3955.

Full text

Abstract:

Abstract Introduction: CPX-351 (Vyxeos) is a novel liposomal formulation of cytarabine and daunorubicin in a fixed 5:1 molar ratio that has been studied in a phase III clinical trial for secondary acute myeloid leukemia. The current study investigated pharmacokinetic and pharmacodynamic relationships of this liposomal formulation. Methods: CPX-351 pharmacokinetic data from a Phase I study of patients (median age: 62, range 24-81 years) with relapsed and refractory acute myeloid leukemia were used for the analysis. CPX-351 was given as a 90-minute infusion on days 1, 3, and 5 of induction thera

APA, Harvard, Vancouver, ISO, and other styles

7

Alves, Ana Catarina, Daniela Ribeiro, Miguel Horta, José L. F. C. Lima, Cláudia Nunes, and Salette Reis. "A biophysical approach to daunorubicin interaction with model membranes: relevance for the drug's biological activity." Journal of The Royal Society Interface 14, no. 133 (2017): 20170408. http://dx.doi.org/10.1098/rsif.2017.0408.

Full text

Abstract:

Daunorubicin is extensively used in chemotherapy for diverse types of cancer. Over the years, evidence has suggested that the mechanisms by which daunorubicin causes cytotoxic effects are also associated with interactions at the membrane level. The aim of the present work was to study the interplay between daunorubicin and mimetic membrane models composed of different ratios of 1,2-dimyristoyl- sn -glycero- 3 -phosphocholine (DMPC), sphingomyelin (SM) and cholesterol (Chol). Several biophysical parameters were assessed using liposomes as mimetic model membranes. Thereby, the ability of daunoru

APA, Harvard, Vancouver, ISO, and other styles

8

Albrecht, K. W., S. Leenstra, P. J. M. Bakker, et al. "High concentration of daunorubicin and daunorubicinol in human malignant astrocytomas after systemic administration of liposomal daunorubicin." Clinical Neurology and Neurosurgery 99 (July 1997): S231. http://dx.doi.org/10.1016/s0303-8467(97)82346-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 1184 (2008): 15. http://dx.doi.org/10.2165/00128415-200811840-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Daunorubicin." Reactions Weekly &NA;, no. 562 (1995): 6. http://dx.doi.org/10.2165/00128415-199505620-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Daunorubicin"

1

Golightly, L. "Trypanosmoma brucei : Studies on the uptake and effects of daunorubicin and daunorubicin carrier preparations." Thesis, University of Sunderland, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.375648.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hardman, Mark Alan. "Design of potential antiprotozoal daunorubicin derivatives." Thesis, De Montfort University, 1985. http://hdl.handle.net/2086/10737.

Full text

Abstract:

Daunorubicin is an antitumour antibiotic which is highly active against the sleeping sickness parasite Trypanosoma rhodesiense in vitro, but which lacks in vivo activity. The object of this work was to modify daunorubicin so as to promote in vivo activity, and to study the mechanism by which daunorubicin is trypanocidal. A series of daunorubicin analogues, and derivatives in which daunorubicin was linked to a macromolecular carrier (known as daunorubicin conjugates) were prepared, and tested against trypanosome infected mice. Only daunorubicin conjugates in which drug was linked to the carrier

APA, Harvard, Vancouver, ISO, and other styles

3

Mohammed, Lina Yousif. "Studies on daunorubicin and actinorhodin type II polyketide synthases." Thesis, University of Bristol, 2018. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.761209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Wattana-Amorn, Pakorn. "Studies on the actinorhodin and daunorubicin type II polyketide synthases." Thesis, University of Bristol, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.441375.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bartels, Anna-Maria. "Durchflusszytometrische Untersuchungen zur zellulären Pharmakokinetik von freien und liposomal verkapseltem Daunorubicin." [S.l.] : [s.n.], 2002. http://deposit.ddb.de/cgi-bin/dokserv?idn=965428001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Maharaj, Vanitha. "A vibrational circular dichroism study of deoxyoctanucleotides and their daunorubicin complexes." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp05/nq20751.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bartels, Anna-Maria. "Durchflußzytometrische Untersuchungen zur zellulären Pharmakokinetik von freien und liposomal verkapseltem Daunorubicin." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2002. http://dx.doi.org/10.18452/14780.

Full text

Abstract:

In dieser Arbeit wurde die zelluläre Pharmakokinetik mit den Teilaspekten Invasion, Evasion und intrazellulärer Verteilung sowie die Apoptoseinduktion als Parameter der Pharmakodyna- mik von zwei Anthrazyklinen, dem freien und liposomal verkapseltem Daunorubicin unter- sucht. Die Versuche wurden anhand einer T-lymfatischen Zelllinie, den CEM-Zellen, durchgeführt. Mittels Durchflußzytometer und konfokaler Lasermikroskop wurde die intrazelluläre Fluoreszenz gemessen, die der intrazellulären Konzentration entsprach. Es zeigte sich, dass freies Daunorubicin anfangs deutlich schneller in die Zell

APA, Harvard, Vancouver, ISO, and other styles

8

Battisti, Robert F. "Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance." Connect to resource, 2007. http://hdl.handle.net/1811/25067.

Full text

Abstract:

Thesis (Honors)--Ohio State University, 2007.<br>Title from first page of PDF file. Document formatted into pages: contains 48 p.; also includes graphics. Includes bibliographical references (p. 46-48). Available online via Ohio State University's Knowledge Bank.

APA, Harvard, Vancouver, ISO, and other styles

9

Masquelier, Michèle. "Leukemia chemotherapy : experimental studies on pharmacological optimisation /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7140-046-X/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Knaust, Eva. "Experimental studies on multidrug resistance in human leukaemia : role of cellular heterogeneity for daunorubicin kinetics /." Linköping : Dept. of Medicine and Care, Univ, 2005. http://www.bibl.liu.se/liupubl/disp/disp2005/med901s.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Daunorubicin"

1

Hardman, Mark Alan. Design of potential antiprotozoal daunorubicin derivatives. Leicester Polytechnic, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Eikel, Daniel. Entwicklung Eines Bestimmungsverfahrens Für Liposomal Verkapseltes Daunorubicin. Diplomarbeiten Agentur diplom.de. ein Imprint der Diplomica, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Steidtmann, Kay. Veränderungen von Morphologie und Wachstum zweier humaner Tumorzellinien in vitro induzierter Daunorubicin-Resistenz. 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Böhm, Dania. Aufnahme von I-123- und Tc-99m-Doxorubicin verglichen mit Tl-201 in Daunorubicin-sensitive und -resistente Magenkarzinomzellen. 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Daunorubicin"

1

Mader, Ines, Patrizia Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola, and Sabine M. Wassertheurer. "Daunorubicin." In Paravasation von Zytostatika. Springer Vienna, 2002. http://dx.doi.org/10.1007/978-3-7091-3799-4_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Mader, Ines, Patrizia Fürst-Weger, Robert Mader, Elisabeth Nogler-Semenitz, and Sabine Wassertheurer. "Daunorubicin." In Extravasation of Cytotoxic Agents. Springer Vienna, 2010. http://dx.doi.org/10.1007/978-3-211-88893-3_26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mader, Ines, Patrizia E. Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola, and Sabine M. Wassertheurer. "Daunorubicin." In Extravasation of Cytotoxic Agents. Springer Vienna, 2003. http://dx.doi.org/10.1007/978-3-7091-3710-9_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mader, Ines, Patrizia Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola, and Sabine M. Wassertheurer. "Daunorubicin liposomal." In Paravasation von Zytostatika. Springer Vienna, 2002. http://dx.doi.org/10.1007/978-3-7091-3799-4_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mader, Ines, Patrizia Fürst-Weger, Robert Mader, Elisabeth Nogler-Semenitz, and Sabine Wassertheurer. "Daunorubicin liposomal." In Extravasation of Cytotoxic Agents. Springer Vienna, 2010. http://dx.doi.org/10.1007/978-3-211-88893-3_27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mader, Ines, Patrizia E. Fürst-Weger, Robert M. Mader, Elisabeth I. Semenitz, Robert Terkola, and Sabine M. Wassertheurer. "Daunorubicin liposomal." In Extravasation of Cytotoxic Agents. Springer Vienna, 2003. http://dx.doi.org/10.1007/978-3-7091-3710-9_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Martin, R. Bruce. "Tetracyclines and Daunorubicin." In Metal Ions in Biological Systems. CRC Press, 2024. http://dx.doi.org/10.1201/9781003573630-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Chaires, Jonathan B. "Molecular Recognition of DNA by Daunorubicin." In ACS Symposium Series. American Chemical Society, 1994. http://dx.doi.org/10.1021/bk-1995-0574.ch010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Shrestha, Biplav, Anaya Raj Pokhrel, Sumangala Darsandhari, Prakash Parajuli, Jae Kyung Sohng, and Ramesh Prasad Pandey. "Engineering Streptomyces peucetius for Doxorubicin and Daunorubicin Biosynthesis." In Environmental Chemistry for a Sustainable World. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-01881-8_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Knaust, E., A. Gruber, A. Porwit-MacDonald, and C. Peterson. "Functional Studies of Daunorubicin Transport in Human Leukemic Cells." In Haematology and Blood Transfusion / Hämatologie und Bluttransfusion. Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-71960-8_68.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Daunorubicin"

1

Sheng, Xia, Jean-Hugues Parmentier, Jonathan Tucci, et al. "Abstract 2960: Adipocytes sequester and metabolize daunorubicin." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-2960.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rios-Doria, Jonathan, Tara L. Costich, Adam Carie, and Kevin Sill. "Abstract 4453: Development of a crosslinked, daunorubicin-loaded micelle with superior pharmacokinetics compared to free daunorubicin and with tunable stability." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4453.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Osdal, Tereza, Lars P. Jordheim, Mihaela Popa, et al. "Abstract 3274: Combination of elacytarabine and daunorubicin is significantly more effective than combination of cytarabine and daunorubicin in primary patient xenografts of AML." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sheng, Xia, Jonathan Tucci, James Behan, and Steven D. Mittelman. "Abstract 172: Adipocytes decrease daunorubicin concentration in acute lymphoblastic leukemia cells." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-172.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Parmentier, Jean-Hugues, Christina M. Dieli-Conwright, and Steven D. Mittelman. "Abstract 3185: Adipocyte-derived hydrogen peroxide promotes chemoresistance to daunorubicin in leukemia cells." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-3185.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Zahariev, Nikolay, and Bissera Pilicheva. "Development of casein-fucoidan nanocomposites as a potential drug delivery system for daunorubicin." In VI. Symposium of Young Researchers on Pharmaceutical Technology,Biotechnology and Regulatory Science. Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Faculty of Pharmacy, 2024. http://dx.doi.org/10.14232/syrptbrs.2024.39.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Sheng, Xia, Jonathan Tucci, and Steven D. Mittelman. "Abstract 1247: Reduction of oxidative stress promotes daunorubicin resistance in acute lymphoblastic leukemia cells." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-1247.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Costich, Tara Lee, Rick Crouse, Adam Carie, et al. "Abstract 1317: IT-143: A nanoparticle delivery platform that encapsulates daunorubicin and widens therapeutic window." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1317.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Contente, Thais C., Iara F. Kretzer, Durvanei A. Maria, Tathiana Capeto, Ricardo Fock, and Raul C. Maranhao. "Abstract 2656: Association of daunorubicin to a lipidic nanoemulsion (NEM-ODNR) - in vivo tumor growth inhibition." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2656.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lin, Tara L., John M. Perry, Xi He, et al. "Abstract CT103: Low-dose daunorubicin to target leukemia stem cells in newly diagnosed and relapsed/refractory AML." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-ct103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!